Evidence map›Paper›PMID 30266781›Full record

ArticleCMAJ open

Canadian status of "drugs to avoid" in 2017: a descriptive analysis.

Joel Lexchin

Abstract read
In one paragraph

Article in CMAJ open. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Information on medicines: Does independence from industry influence matter?African journal of primary health care & family medicine · 2024
    Article
  3. Article
  4. Article
  5. "Drugs to avoid" to improve quality use of medicines: how is Australia faring?Journal of pharmaceutical policy and practice · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Joel LexchinSchool of Health Policy and Management, York University; University Health Network; Faculty of Medicine, University of Toronto, Toronto, Ont. jlexchin@yorku.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe independent French drug bulletin,

methodsThis descriptive analysis reviewed a list of drugs compiled by

results

interpretationMany drugs that

Identifiers

PMID30266781
PMCPMC6182123

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.